Sugi Predict

Sugi Predict / Compounds / SCHEMBL545919

SCHEMBL545919

SCHEMBL545919

O=C(O)C1=Cc2cc(O)ccc2OC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.46
▸ KMT2A Q03164 5/20 0.46
▸ HTT P42858 2/20 0.46
▸ NR1H4 Q96RI1 3/20 0.44
▸ ALOX5 P09917 2/20 0.43
▸ MAPT P10636 7/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MAOB P27338 4/20 0.40
▸ SHMT2 P34897 1/20 0.40
▸ TP53 P04637 2/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ HSP90AA1 P07900 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAOA P21397 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28804341 0.83 ALDH1A1 (0.50) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL3187719 0.83 MEN1 (0.46) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL416748 0.82 MAPT (0.56) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL20839505 0.82 MEN1 (0.48) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL432482 0.82 MEN1 (0.66) MEN1KMT2AHTTALOX5MAPT
SCHEMBL24229499 0.81 NR1H4 (0.49) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL31538745 0.80 ALOX5 (0.57) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL3198679 0.78 MAOB (0.64) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL13366369 0.78 CA12 (0.51) MEN1KMT2AHTTNR1H4ALOX5
SCHEMBL6364809 0.78 PTGS1 (0.53) MEN1KMT2AHTTNR1H4ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049079-A1 CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2026-02-19 — — US claimed
CN-116348465-A Chiral synthesis of fused bicyclic RAF inhibitors 爵士制药爱尔兰有限公司 2023-06-27 — — CN claimed
EP-4188923-A1 CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS Jazz Pharmaceuticals Ireland Limited (IE) 2023-06-07 — — EP claimed
WO-2022023450-A1 CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2022-02-03 — — WO claimed
US-20260092063-A1 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2026-04-02 — — US disclosed
US-20260049079-A1 CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2026-02-19 — — US disclosed
US-12304912-B2 Fused bicyclic RAF inhibitors and methods for use thereof JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2025-05-20 — — US disclosed
US-20240124452-A1 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE 2024-04-18 — — US disclosed
US-11858930-B2 Fused bicyclic RAF inhibitors and methods for use thereof JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2024-01-02 — — US disclosed
US-11858930-B2 Fused bicyclic RAF inhibitors and methods for use thereof JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2024-01-02 — — US disclosed
US-11858930-B2 Fused bicyclic RAF inhibitors and methods for use thereof JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2024-01-02 — — US disclosed
CN-116601150-A Fused bicyclic RAF inhibitors and methods of use thereof 爵士制药爱尔兰有限公司 2023-08-15 — — CN disclosed
US-8110687-B2 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-07 — — US disclosed
CN-101365682-A Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARM INC (US) 2009-02-11 — — CN disclosed
EP-1957460-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-08-20 — — EP disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 — — US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 — — US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 — — US disclosed
WO-2007067444-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-14 — — WO disclosed
WO-2007067444-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304912-B2 Fused bicyclic RAF inhibitors and methods for use thereof BRAF, RAF1, NRAS MEN1 1786/4885KMT2A 2994/4885HTT 4084/4885
US-11858930-B2 Fused bicyclic RAF inhibitors and methods for use thereof BRAF, RAF1, NRAS MEN1 1786/4885KMT2A 2994/4885HTT 4084/4885
US-20260049079-A1 CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS BRAF, HRAS, RAF1 MEN1 3267/4885KMT2A 3973/4885HTT 3138/4885
US-20240124452-A1 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF BRAF, RAF1, NRAS MEN1 1786/4885KMT2A 2994/4885HTT 4084/4885
US-20260092063-A1 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF BRAF, NRAS, RAF1 MEN1 1965/4885KMT2A 2483/4885HTT 4367/4885
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MAP3K20, MAP3K1, MAP3K5 MEN1 2916/4885KMT2A 1162/4885HTT 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.